Novavax Inc vs Xcel Energy Inc — how do they compare? Novavax Inc trades at $7.95 (market cap $1.31B), while Xcel Energy Inc trades at $78.34 (market cap $48.51B). The key difference: Xcel Energy Inc is far larger — about 37× Novavax Inc's market cap, and Xcel Energy Inc pays a 3.05% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | XEL | |
|---|---|---|
Market Cap | $1.31B | $48.51B |
Sector | Health | Utilities |
52-Week High | $11.19 | $83.91 |
52-Week Low | $6.22 | $71.75 |
Enterprise Value | $889.30M | $86.82B |
Dividend Yield | — | 3.05% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
XEL trades at $78.09, up 1.59% today, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings beat expectations in Q2 2026 with EPS of $0.93, driven by infrastructure investments. The company maintains solid fundamentals, including a 15.28% net income margin and a $0.59 quarterly dividend, while analyst consensus is bullish with a $93.80 price target.
Outlook is positive due to strong earnings growth and a $60 billion capital plan supporting future expansion, but risks include regulatory pushback and high debt levels. The stock offers stability with a 2.87% dividend yield, though technical resistance near $79 may limit near-term gains.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →